MYC Degradation
Open accessThe DOI matches its Crossref record; 111 of the 114 references it cites were found in a registry or an index.
Abstract
The MYC oncoprotein is an essential transcription factor that regulates the expression of many genes involved in cell growth, proliferation, and metabolic pathways. Thus, it is important to keep MYC activity in check in normal cells in order to avoid unwanted oncogenic changes. Normal cells have adapted several ways to control MYC levels, and these mechanisms can be disrupted in cancer cells. One of the major ways in which MYC levels are controlled in cells is through targeted degradation by the ubiquitin-proteasome system (UPS). Here, we discuss the role of the UPS in the regulation of MYC protein levels and review some of the many proteins that have been shown to regulate MYC protein stability. In addition, we discuss how this relates to MYC transcriptional activity, human cancers, and therapeutic targeting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We show that DT-061 binds a unique heterotrimeric regulatory pocket to selectively stabilize the B56α-PP2A holoenzyme thereby inducing cell death and attenuating tumor growth through B56α directed substrate dephosphorylation, including its most well characterized substrate, the oncogenic protein c-MYC (Allen-Petersen et al., 2018; Arnold and Sears, 2006; Farrell and Sears, 2014; Sheppard et al., 2”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Farrell and Sears, 2014
Citations
Cites
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Max: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with Myc
Blackwood, E. M., & Eisenman, R. N. (1991) · Science · doi:10.1126/science.2006410 · Cited by 1,697
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Self-citationc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
SCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,242
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Cited by
Items 201–300 of 471
Mo, X., Shen, X., Mo, X., Yu, F., Tan, W., Deng, Z., He, J., Luo, Z., Chen, Z., & Yang, J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115446 · Cited by 19
When Just One Phosphate Is One Too Many: The Multifaceted Interplay between Myc and Kinases
Boi, D., Rubini, E., Breccia, S., Guarguaglini, G., & Paiardini, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054746 · Cited by 22
“, acetylation and methylation, contribute to regulating Myc activity and stability [27].”
BackgroundLiu, Y., Zhang, Y., Ran, L.-Y., Huang, B., Ren, J.-W., Ma, Q., Pan, X., Yang, F.-F., Liang, C., Wang, X.-L., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05225-4 · Cited by 22
“C-Myc has a short half-life of only 30 min, after which it undergoes degradation through the ubiquitin-proteasome pathway [38].”
BackgroundCDK9 inhibitors for the treatment of solid tumors
Mo, C., Wei, N., Li, T., Bhat, M. A., Mohammadi, M., & Kuang, C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116470 · Cited by 23
Anticancer potential of active alkaloids and synthetic analogs derived from marine invertebrates
Cai, C., Yang, D., Cao, Y., Peng, Z., Wang, Y., Xi, J., Yan, C., & Li, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116850 · Cited by 19
Yu, V. Z., Ko, J. M. Y., Ning, L., Dai, W., Law, S. Y.-K., & Lung, M. L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.005 · Cited by 19
Hu, X., & Chen, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00179 · Cited by 22
Insights about MYC and Apoptosis in B-Lymphomagenesis: An Update from Murine Models
Vecchio, E., Fiume, G., Correnti, S., Romano, S., Iaccino, E., Mimmi, S., Maisano, D., Nisticò, N., & Quinto, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124265 · Cited by 22
“The expression of MYC protein is tightly regulated, at transcriptional, post-transcriptional and, post-translational level [10–12] in normal tissue, with a half-life of ~20 min [13].”
Yu, H. T., He, J., Liu, W., Feng, S., Gao, L., Xu, Y., Zhang, Y., Hou, X., Zhou, Y., Yang, L., et al. (2021) · Hepatology · doi:10.1002/hep.31870 · Cited by 22
“To uncover the mechanism of how AF9 stabilizes the cMyc protein, we initially tested whether the interaction between AF9 and cMyc contributes to the phosphorylation level of cMyc at S62.”
BackgroundInfluentialYao, R., Xie, Y., Sun, X., Zhang, M. H., Zhou, J. W., Liu, L., Gao, J., & Xu, K. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s264077 · Cited by 19
“one of the most prominent mechanisms for c-Myc degradation.(16) Hence, c-Myc can be easily and rapidly”
BackgroundNagasaka, M., Inoue, Y., Yoshida, M., Miyajima, C., Morishita, D., Tokugawa, M., Nakamoto, H., Sugano, M., Ohoka, N., & Hayashi, H. (2022) · FEBS Letters · doi:10.1002/1873-3468.14296 · Cited by 21
“When cells enter the G 1 phase, the expression of the c-Myc protein is rapidly upregulated; however, its half-life is approximately 30 min [9,10]. c-Myc is frequently overexpressed in cancer cells, suggesting a failure in its quantitative regulatory mechanism.”
BackgroundZhou, M., Boulos, J. C., Omer, E. A., Klauck, S. M., & Efferth, T. (2023) · Molecules · doi:10.3390/molecules28155658 · Cited by 18
“The ubiquitination-proteasome pathway is one of the prime mechanisms to degrade c-MYC [10,48].”
BackgroundBergkamp, N. D., van Senten, J. R., Brink, H. J., Bebelman, M. P., van den Bor, J., Çobanoğlu, T. S., Dinkla, K., Köster, J., Klau, G. W., Siderius, M. H., et al. (2023) · Science Signaling · doi:10.1126/scisignal.ade6737 · Cited by 17
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
Giacomini, A., Taranto, S., Gazzaroli, G., Faletti, J., Capoferri, D., Marcheselli, R., Sciumé, M., Presta, M., Sacco, A., & Roccaro, A. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03217-2 · Cited by 22
“1) [25, 31].”
BackgroundSolares, S., León, J., & García-Gutiérrez, L. (2024) · Cancers · doi:10.3390/cancers16244212 · Cited by 21
“Moreover, the fact that MYC induces the expression of the virus receptor, CR2/CD21, will also favor the EBV infection in B cells already carrying the MYC translocation.”
Zhang, F., Zakaria, S. M., Tabor, V., Singh, M., Tronnersjö, S., Goodwin, J., Selivanova, G., Bártek, J., Castell, A., & Larsson, L. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1553339 · Cited by 19
“A third explanation is that MYC expression is down-regulated as a result of DDR and apoptotic signaling triggered by MYC itself [40,57].”
BackgroundPTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis
Li, C., Li, S., Huang, X.-C., Chen, J., Liu, W., Zhang, X., Song, X., & Du, R. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.08.001 · Cited by 18
MICAL-L2 Is Essential for c-Myc Deubiquitination and Stability in Non-small Cell Lung Cancer Cells
Min, P., Zhang, L., Wang, Y., Qi, C., Song, Y., Bibi, M., Zhang, Y., Ma, Y., Zhao, X., Yu, M.-J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.575903 · Cited by 18
Xiao, D., He, J., Guo, Z., He, H., Yang, S., Huang, L., Pan, H., & He, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.571384 · Cited by 19
“Through CHX chase assay, we have found that RHPN2 stabilized c-Myc protein via phosphorylation of c-Myc at Ser62 in lung cancer.”
BackgroundInfluentialNotch activation promotes endothelial quiescence by repressing MYC expression via miR-218
Sun, J., Dou, G., Yang, Z., Liang, L., Duan, J., Ruan, B., Li, M., Chang, T., Xu, X., Chen, J., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.07.023 · Cited by 22
Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs
Ciaccio, R., Rosa, P. D., Aloisi, S., Viggiano, M., Cimadom, L., Zadran, S. K., Perini, G., & Milazzo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312883 · Cited by 23
Réthi‐Nagy, Z., Ábrahám, E., Udvardy, K., Klement, É., Darula, Z., Pál, M., Katona, R. L., Tubak, V., Páli, T., Kóta, Z., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158168 · Cited by 18
“We chose c-Myc, a transcription factor controlling several essential cellular processes [14] because it has an extended intrinsically unstructured region and its concentration is tightly regulated by a variety of post-translational modifications, which influence its proteasome-dependent degradation [15,16].”
BackgroundChen, J., Lin, X., He, J., Liu, J., He, J., Tao, C., & Wang, Q. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106063 · Cited by 17
Maués, J. H. D. S., Ribeiro, H. F., Pinto, G. R., Lopes, L. D. O., Lamarão, L. M., Pessoa, C. M. F., Moreira-Nunes, C. A., de Carvalho, R. M., de Assumpção, P. P., REY, J. A., et al. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/5804376 · Cited by 21
Tian, L., Li, Y., Chang, R., Zhang, P., Zhang, J., & Huo, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9567 · Cited by 24
“…transcription regulator, the activation of c‑Myc may accelerate cell cycle progression and induce cell apoptosis (13). c‑Myc is upregulated in various types of malignant tumor, including colorectal cancer, and is considered compulsory for the uncontrolled proliferation of cancer cells (14).”
Ge, H., Zhang, D., Shi, M., Lian, X., & Zhang, Z. (2021) · Marine Drugs · doi:10.3390/md19020079 · Cited by 16
“Although c-Myc inhibition would be a powerful approach for the treatment of cancers, strategies to directly target c-Myc have not yet been achieved because c-Myc is easy to be degraded through the ubiquitin-proteasome pathway [25,28].”
BackgroundTargeting MYC-driven lymphoma: lessons learned and future directions
Martínez-Martín, S., Beaulieu, M.-È., & Soucek, L. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.127 · Cited by 18
The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage
Jin, C., Einig, E., Xu, W., Kollampally, R. B., Schlösser, A., Flentje, M., & Popov, N. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae004 · Cited by 17
“MYC is a short-lived protein and its function is stringently controlled by the ubiquitin system ( 32 ,33 ).”
GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival
Petrusca, D. N., Mulcrone, P. L., Macar, D. A., Bishop, R. T., Berdyshev, E. V., Suvannasankha, A., Anderson, J. L., Sun, Q., Auron, P. E., Galson, D. L., et al. (2022) · Cancers · doi:10.3390/cancers14030772 · Cited by 18
“Phosphorylation of c-Myc at Serine 62 (S62) initiated by the ERK cascade or cyclin-dependent kinases (CDKs) [33] enhances c-Myc’s stability and its DNA binding and target gene regulation.”
BackgroundTranslational and post-translational regulation of mouse cation transport regulator homolog 1
Nomura, Y., Hirata, Y., Kiuchi, K., & Oh‐hashi, K. (2016) · Scientific Reports · doi:10.1038/srep28016 · Cited by 19
Hurd, M., Pino, J. J., Jang, K., Allevato, M. M., Vorontchikhina, M., Ichikawa, W., Zhao, Y., Gates, R., Villalpando, E., Hamilton, M., et al. (2023) · Genes & Development · doi:10.1101/gad.350736.123 · Cited by 17
“…but also its subnuclear localization and/or transcriptional activity (Chou et al. 1995; Kim et al. 2003; von der Lehr et al. 2003; Hann 2006; Vervoorts et al. 2006; Farrell and Sears 2014; Sabò et al. 2014; González-Prieto et al. 2015; Jaenicke et al. 2016; Su et al. 2018; Sun et al. 2018).”
NSD3S stabilizes MYC through hindering its interaction with FBXW7
González-Pecchi, V., Kwan, A. K., Doyle, S. P., Ivanov, A. A., Du, Y., & Fu, H. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz098 · Cited by 17
“Different regulatory mechanisms have been reported to alter MYC protein stability that could directly impact MYC signaling under physiological and pathological conditions (Farrell and Sears, 2014).”
BackgroundDual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma
Huang, X., Liu, Y., Wang, Y., Bailey, C., Zheng, P., & Liu, Y. (2021) · Cancers · doi:10.3390/cancers13040694 · Cited by 17
“A number of proteins have been shown to regulate stability of MYC [29].”
BackgroundKolloch, L. J., Kreinest, T., Meisterernst, M., & Oeckinghaus, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020812 · Cited by 15
“Perhaps related to this, we do see upregulation of the Myc ubiquitin-conjugating enzyme E2, as well as ubiquitin ligase Trim32 and Myc-destabilizing GSK3-β, while the Myc-stabilizing ligases Usp28, Sirt2 and β-Trc are downregulated after extended inhibition [63].”
BackgroundLv, P., & Xue, Y. (2021) · Bioengineered · doi:10.1080/21655979.2021.1935404 · Cited by 18
“c-Myc is the gene product of MYC, an oncogene that can facilitate tumorigenesis in many human tumors [27].”
BackgroundSulfonamide Inhibitors of β‐Catenin Signaling as Anticancer Agents with Different Output on c‐MYC
Magno, L. D., Pastena, F. D., Puxeddu, M., Regina, G. L., Coluccia, A., Ciogli, A., Manetto, S., Maroder, M., Canettieri, G., Silvestri, R., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000594 · Cited by 14
Type IV collagen α5 chain promotes luminal breast cancer progression through c-Myc-driven glycolysis
Wu, Y., Liu, X., Zhu, Y., Qiao, Y., Gao, Y., Chen, J., & Ge, G. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac068 · Cited by 20
“Phosphorylation on Ser62 of c-Myc increases its transcriptional activity ( Farrell and Sears, 2014 ) .”
MYC overrides HIF-1α to regulate proliferating primary cell metabolism in hypoxia
Copeland, C. A., Olenchock, B. A., Ziehr, D. R., McGarrity, S., Leahy, K., Young, J. D., Loscalzo, J., & Oldham, W. M. (2023) · eLife · doi:10.7554/elife.82597 · Cited by 15
Gene expression association study in feline mammary carcinomas
Ferreira, D., Martins, B., Soares, M., Correia, J., Adega, F., Ferreira, F., & Chaves, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221776 · Cited by 15
Annexin A2 binds the internal ribosomal entry site of c-myc mRNA and regulates its translation
Strand, E., Hollås, H., Sakya, S. A., Romanyuk, S. A., Saraste, M. E. V., Grindheim, A. K., Patil, S. S., & Vedeler, A. (2021) · RNA Biology · doi:10.1080/15476286.2021.1947648 · Cited by 19
“The highly complex regulation of c-Myc expression is modulated by several signal transduction pathways at multiple levels, including transcription [15,16], translation [23] as well as stability of the mRNA [24] and protein [25].”
BackgroundPerumal, N., Kanchan, R. K., Doss, D., Bastola, N., Atri, P., Chirravuri‐Venkata, R., Thapa, I., Vengoji, R., Maurya, S. K., Klinkebiel, D. L., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01299-z · Cited by 15
A systematic review of molecular alterations in invasive non-functioning pituitary adenoma
Hosseinkhan, N., Honardoost, M., Emami, Z., Cheraghi, S., Hashemi‐Madani, N., & Khamseh, M. E. (2022) · Endocrine · doi:10.1007/s12020-022-03105-9 · Cited by 15
Tu, X., Li, C., Sun, W. Y., Tian, X., Li, Q., Wang, S., Ding, X., & Huang, Z. (2023) · Cancers · doi:10.3390/cancers15030930 · Cited by 19
“MYC stability is tightly regulated by the ubiquitination system, and MYC is targeted for degradation by the ubiquitin–proteasome pathway after the ubiquitination by SCFFBXW7 and several other E3 ligases [26].”
BackgroundScully, K. M., Lahmy, R., Signaevskaia, L., Šášik, R., Medal, R., Kim, H. J., French, R. P., James, B. P., Wu, Y., Lowy, A. M., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.05.002 · Cited by 14
“Because MYC also is regulated critically via protein stability, we examined its expression by Western blot.(41) Strikingly, MYC protein levels significantly decreased in all 5 cell lines, including MIA PaCa-2, indicating that E47 can regulate MYC expression at multiple levels (Figure 6A).”
BackgroundInfluentialSriratanasak, N., Petsri, K., Laobuthee, A., Wattanathana, W., Vinayanuwattikun, C., Luanpitpong, S., & Pithi Chanvorachote, B. (2020) · Molecular Pharmacology · doi:10.1124/mol.120.119719 · Cited by 15
“Whereas phosphorylation at S62 causes the protein to become more stable, phosphorylation at T58 facilitates the ubiquitin-proteasomal degradation (Amati and Sanchez-Arévalo Lobo, 2007; Conacci-Sorrell et al., 2014; Farrell and Sears, 2014).”
BackgroundLi, S., Zhang, L., Zhang, G., Shangguan, G., Hou, X., Duan, W., Xi, Y., Xu, N., Zhang, B., Dong, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103296 · Cited by 15
“To further determine the detailed molecular mechanism by which ATG5 regulates c-Myc protein degradation under normal culture conditions, we examined whether ATG5 associates with the reported E3 ubiquitin-protein ligases (including FBW7, SKP2, CHIP, and TRIM32) (Farrell and Sears, 2014; Paul et al., 2013; Schwamborn et…”
BackgroundInfluentialSchaafsma, E., Zhao, Y., Zhang, L., Li, Y., & Cheng, C. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0526 · Cited by 12
“org Mol Cancer Res; 19(3) March 2021 415”
BackgroundInfluentialChen, J., Zhang, S., Huang, X., Wang, Q., Xu, W., Huang, J., Su, Y., Sun, Q., Du, X., Xing, B., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101140 · Cited by 16
“Previous studies show that c-Myc protein can be rapidly stabilized through T58/S62 phosphorylation, which prevents the targeted degradation of c-Myc by the UPS [19].”
Dai, M., Sridhar, R., Li, R., Tan, R., Yan, K., Fan, G., & Liu, M. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221095950 · Cited by 16
Deng, L., Wan, J., Cheng, A., Wang, M., Tian, B., Wu, Y., Yang, Q., Ou, X., Mao, S., Sun, D., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.876820 · Cited by 13
“Meanwhile, several reports have suggested that the protein expression level and stability were increased after phosphorylation by reducing their ubiquitination-mediated degradation (Farrell and Sears, 2014; Liu et al., 2017; Liang et al., 2020).”
BackgroundInterferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation
Bahram, F., Hydbring, P., Tronnersjö, S., Zakaria, S. M., Frings, O., Fahlén, S., Nilsson, H., Goodwin, J., von der Lehr, N., Su, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6693 · Cited by 13
“IFN-γ/p27-induced degradation of Myc is independent of Thr-58 phosphorylation and the E3 ligases SCFFbxw7 and of SCFSkp2, which have been connected to Myc turnover previously, the former through MB1 and the latter connected to p27 [12, 19, 20, 23, 24].”
BackgroundMethodInfluentialRicker, E., Verma, A., Marullo, R., Gupta, S. K., Ye, C., Pannellini, T., Manni, M., Tam, W., Inghirami, G. G., Elemento, O., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69884-1 · Cited by 12
Chen, L., Cheng, B., Sun, Q., & Lai, L. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127711 · Cited by 13
c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer
Signorile, M. L., Grossi, V., Fasano, C., Forte, G., Disciglio, V., Sanese, P., Marco, K. D., Rocca, F. L., Armentano, R., Valentini, A. M., et al. (2022) · Cancers · doi:10.3390/cancers14194840 · Cited by 15
“Doubly phosphorylated c-MYC is then recognized by the PIN1 isomerase, which catalyzes the isomerization of the S62-proline 63 bond from a cis conformation to a trans conformation [38].”
BackgroundInfluentialBi, L., Xie, C., Jiao, L., Jin, S., Hnit, S. S. T., Mu, Y., Wang, Y., Wang, Q., Ge, G., Wang, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14897 · Cited by 13
Becker, S., Kiecke, C., Schäfer, E., Sinzig, U., Deuper, L., Trigo‐Mouriño, P., Griesinger, C., Koch, R., Rydzyńska, Z., Chapuy, B., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1203 · Cited by 15
Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
Zhang, X., Meng, T., Cui, S., Feng, L., Liu, D., Pang, Q., & Wang, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621294 · Cited by 16
“Myc levels are controlled through targeted degradation by UPS (83).”
BackgroundXiong, K., Chen, S., Xu, H., Tu, S., Weng, H., Wang, Y., Li, M., Yu, J., Qian, K., Ju, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202408311 · Cited by 20
TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC
Yu, J., Li, M., Ju, L., Zhou, F., Wang, Y., Zhang, Y., Zhang, R., Du, W., Huang, R., Qian, K., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02922-0 · Cited by 12
“The degradation process mediated by the ubiquitin-proteasome system is among the pivotal mechanisms regulating MYC levels [19].”
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
Crespiatico, I., Zaghi, M., Mastini, C., D’Aliberti, D., Mauri, M., Mercado, C. M., Fontana, D., Spinelli, S., Crippa, V., Inzoli, E., et al. (2024) · Blood · doi:10.1182/blood.2023021349 · Cited by 12
Yang, Y., Mao, H. Z., Chen, L., & Li, L. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108776 · Cited by 12
Palanivel, C., Chaudhary, N., Seshacharyulu, P., Cox, J. L., Yan, Y., Batra, S. K., & Ouellette, M. M. (2022) · Neoplasia · doi:10.1016/j.neo.2022.01.002 · Cited by 13
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1 -Fusion-Positive Lung Cancer
Iyer, S. R., Odintsov, I., Schoenfeld, A. J., Siau, E., Mattar, M. S., de Stanchina, E., Khodos, I., Drilon, A., Riely, G. J., Ladanyi, M., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0025 · Cited by 11
Novel UHRF1-MYC Axis in Acute Lymphoblastic Leukemia
Park, S., Sater, A. H. A., Fahrmann, J. F., Irajizad, E., Cai, Y., Katayama, H., Vykoukal, J. V., Kobayashi, M., Dennison, J. B., Garcia‐Manero, G., et al. (2022) · Cancers · doi:10.3390/cancers14174262 · Cited by 12
“The regulation of the c-Myc protein expression is controlled through complex systems, including targeted degradation by the ubiquitin-proteasome system [40].”
BackgroundMiyake-Stoner, S. J., & O’Shea, C. C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.022 · Cited by 12
Thevenon, D., Seffouh, I., Pillet, C., Crespo-Yàñez, X., Fauvarque, M., & Taillebourg, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00506 · Cited by 12
Tang, M., Xie, X., Shi, M., Xin, W., Zheng, G., Zhang, Y., Zhang, Z., & Lian, X. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153383 · Cited by 12
The black sheep of class IIa: HDAC7 SIKens the heart
Travers, J. G., Hu, T., & McKinsey, T. A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137074 · Cited by 11
Vízkeleti, L., & Spisák, S. (2023) · Cells · doi:10.3390/cells12131745 · Cited by 12
Identification of antimycin A as a c-Myc degradation accelerator via high-throughput screening
Liu, Z., Ishikawa, K., Sanada, E., Semba, K., Li, J., Li, X., Osada, H., & Watanabe, N. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105083 · Cited by 11
“When the pT58 of c-Myc is recognized by E3 ubiquitin ligase, c-Myc is ubiquitinated and degraded by 26S proteasome (13, 14, 31).”
BackgroundGunasinghe, K. K. J., Rahman, T., & Wezen, X. C. (2023) · ACS Omega · doi:10.1021/acsomega.3c05822 · Cited by 11
Zhu, X., Li, C., Gao, Y., Zhang, Q., Wang, T., Zhou, H., Bu, F., Chen, J., Mao, X., He, Y., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02873-0 · Cited by 13
“Notably, c-MYC is known to have a short half-life of 30 min, making it subject to rapid degradation through UPS [32, 33].”
BackgroundChen, C., Liu, Q., Chen, W., Gong, Z., Kang, B., Sui, M., Huang, L., & Wang, Y. (2024) · EMBO Reports · doi:10.1038/s44319-024-00110-z · Cited by 12
“It was previously shown in other cellular systems that MYC suppressed POX/PRODH expression primarily through upregulating miR-23b * (Liu et al, 2012), and the level of MYC is regulated by MEK/ERK pathway: ERK phosphorylates Ser62 and stabilizes MYC proteins (Farrell and Sears, 2014).”
BackgroundAll eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer
Hughes, C. J., Alderman, C., Wolin, A. R., Fields, K. M., Zhao, R., & Ford, H. L. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189098 · Cited by 12
Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies
Liefwalker, D. F., Gabay, M., Wang, Z., Pathak, K. V., Plaisier, S. B., Shah, V. M., Babra, B., Dewson, G. S., Lai, I. K., Mosley, A. R., et al. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00263-8 · Cited by 12
Self-citationZeng, H., Wei, B., Liu, J., Lu, L., Li, L., Wang, B., & Sun, M. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.08.014 · Cited by 12
Li, Z., Tian, J., Chu, Y., Zhu, H., Wang, J., & Huang, J. X. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100512 · Cited by 11
“Given that targeted degradation by the ubiquitin-proteosome system is one of the main ways in which MYC levels are controlled in cells [40], inhibiting PVT1 could be a feasible approach to combat the OS process driven by MYC.”
BackgroundGrowth Signaling Networks Orchestrate Cancer Metabolic Networks
Manning, B. D., & Dibble, C. C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041543 · Cited by 12
Molina, E., García-Gutiérrez, L., Junco, V., Pérez‐Olivares, M., de Yébenes, V. G., Blanco, R. E., Quevedo, L., Acosta, J. C., Marín, A. V., Ulgiati, D., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02846-9 · Cited by 11
“As a positive control, we used 12-O-tetradecanoylphorbol-13-acetate (TPA), reported to induce lytic genes in Raji cells [41].”
MethodApoptotic Effect of Isoimpertorin via Inhibition of c-Myc and SIRT1 Signaling Axis
Ko, H., Park, S., Sim, D. Y., Kim, S., Hur, S., Lee, J., & Kim, Y.-J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084248 · Cited by 10
CRL2KLHDC3 and CRL1Fbxw7 cooperatively mediate c-Myc degradation
Motomura, S., Yumimoto, K., Tomonaga, T., & Nakayama, K. I. (2024) · Oncogene · doi:10.1038/s41388-024-03048-7 · Cited by 10
“Several ubiquitin ligases (E3s) have been shown to contribute to the degradation of c-Myc [11 – 13], with the most well studied of these enzymes being a Cullin-RING ubiquitin ligase complex containing the substrate recognition subunit Fbxw7 (CRL1 Fbxw7 ).”
Wu, Y., & Zhang, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031168 · Cited by 10
“C-Myc harbors a short half-life rigorously regulated by ubiquitination [139,140].”
BackgroundALGhamdi, M. A., Khalifah, T. A., Alhawati, H. S., Ruzayq, M., Alrakaf, A., Khodier, A. E., & Al-Gayyar, M. M. H. (2023) · Cureus · doi:10.7759/cureus.41985 · Cited by 10
“The c-Myc transcription factor is a well-known oncogene that can accelerate cell cycle progression and is upregulated in various malignant tumors [23].”
BackgroundNoncoding RNAs Regulating p53 and c-Myc Signaling
Mei, Y., & Wu, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-1498-7_13 · Cited by 12
CIP2A regulates MYC translation (via its 5′UTR) in colorectal cancer
Denk, S., Schmidt, S., Schurr, Y., Schwarz, G., Schote, F., Diefenbacher, M. E., Armendariz, C., Dejure, F. R., Eilers, M., & Wiegering, A. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03772-y · Cited by 13
“In many cell lines, MYC proteins turn over with a half-life of approximately 20 min [24].”
Leishmania regulates host macrophage miRNAs expression by engaging transcription factor c-Myc
Nandan, D., Rath, C. T., & Reiner, N. E. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ru0920-614r · Cited by 12
Li, H., Zhou, Y., Wang, M., Wang, H., Zhang, Y., Peng, R., Zhang, R., Zhang, M., Zhang, M., Qiu, P., et al. (2021) · Cancer Science · doi:10.1111/cas.15120 · Cited by 10
Imaging-Based Screening of Deubiquitinating Proteases Identifies Otubain-1 as a Stabilizer of c-MYC
Moree, S. E., Maneix, L., Iakova, P. A., Stossi, F., Sahin, E., & Catic, A. (2022) · Cancers · doi:10.3390/cancers14030806 · Cited by 11
“Here, c-MYC binds to DNA, becomes ubiquitinated following activation, and is degraded by the proteasome [26,28].”
BackgroundInfluentialNjomen, E., Vanecek, A. S., Lansdell, T. A., Yang, Y.-T., Schall, P. Z., Harris, C. M., Bernard, M. P., Isaac, D., Alkharabsheh, O. A., Al-Janadi, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10050938 · Cited by 11
“MYC is a highly unstable protein that is regulated by the ubiquitin-proteasome system (UPS), following a series of post-translational modifications [4,11].”
BackgroundInfluentialDNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer
Wei, S., Yang, I., Mohiuddin, I. S., Kshirsagar, G. J., Nguyen, T. H., Trasti, S., Maurer, B. J., & Kang, M. H. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194939 · Cited by 10
A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis
Yao, H., Chen, X., Wang, T., Kashif, M., Qiao, X., Tüksammel, E., Larsson, L., Okret, S., Sayin, V. I., Qian, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112961 · Cited by 11
Hu, F., Zhao, L., Wang, J., Li, X., Xue, Z., Ma, Y., Zheng, M., Chen, C., Tong, M., Guo, X., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119855 · Cited by 10
Tinsley, S. L., Chianis, E. R. D., Shelley, R. A., Mall, G. K., Dhiman, A., Baral, G., Kothandaraman, H., Thoma, M. C., English, I. A., Daniel, C. J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03196-w · Cited by 11
“PP2A-B56α provides critical posttranslational regulation of MYC by dephosphorylating MYC at serine62 (pS62 Myc) and driving MYC proteasomal degradation (19,20).”
Self-citationLiu, C., Jiang, K., Ding, Y., Yang, A., Cai, R., Bai, P., Xiong, M., Fu, C., Quan, M., Xiong, Z., et al. (2023) · Theranostics · doi:10.7150/thno.85421 · Cited by 11
“c-Myc protein regulation has been reported to be achieved by inhibiting mRNA transcription, suppressing translation or promoting protein degradation [51-53].”
BackgroundMethodTadele, D. S., Robertson, J. M., Crispin, R., Herrera, M. C., Chlubnová, M., Piechaczyk, L., Durán, P. A., Singh, S. K., Gedde‐Dahl, T., Fløisand, Y., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015285 · Cited by 9
“Certain Skp, Cullin, Fbox (SCF) complexes can ubiquitinate c-Myc to target it for destruction (28).”
BackgroundInfluentialEmerging Direct Targeting β-Catenin Agents
Nalli, M., Masci, D., Urbani, A., Regina, G. L., & Silvestri, R. (2022) · Molecules · doi:10.3390/molecules27227735 · Cited by 12
“Direct or indirect suppression of c-Myc may slow down or reverse the cancer growth rate [26,27].”
BackgroundT cell help induces Myc transcriptional bursts in germinal center B cells during positive selection
Tikva, S. K. B., Gurwitz, N., Sivan, E., Hirsch, D., Hezroni, H., Biram, A., Moss, L., Wigoda, N., Egozi, A., Monziani, A., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj7124 · Cited by 11
DeVore, S. B., Schuetz, M., Alvey, L., Lujan, H., Ochayon, D. E., Williams, L., Chang, W. C., Filuta, A. L., Ruff, B. P., Kothari, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114589 · Cited by 10
Varano, G., Lonardi, S., Sindaco, P., Pietrini, I., Morello, G., Balzarini, P., Vit, F., Neuman, H., Bertolazzi, G., Brambillasca, S., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0099 · Cited by 12
Proteomic profiles and the function of RBP4 in endometrium during embryo implantation phases in pigs
Wang, Y., Xue, S., Liu, Q., Gao, D., Hua, R., & Lei, M. (2023) · BMC Genomics · doi:10.1186/s12864-023-09278-5 · Cited by 8
Metadata
- Authors
- Farrell, A. S., & Sears, R. C.
- Affiliations
- Oregon Health & Science University (US)
- ORCID
- Sears, R. C.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-03-01
- Volume
- 4
- Issue
- 3
- Pages
- a014365-a014365
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3935390
- OpenAlex
- W4236967220
- Cited by
- 468
- References
- 114
- Citations by year
- 2026: 35 · 2025: 38 · 2024: 46 · 2023: 58 · 2022: 58 · 2021: 53 · 2020: 55 · 2019: 29 · 2018: 28 · 2017: 17 · 2016: 20 · 2015: 17 · 2014: 10
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- Myc oncoprotein, protein degradation, ubiquitin-proteasome system, MYC protein stability, transcriptional regulation, cancer, MYC-targeted therapy, cell proliferation
- MeSH terms
- Acetylation, Cell Communication, Humans, Neoplasms, Transcription, Genetic, Genes, myc, Ubiquitin, Proteasome Endopeptidase Complex, Protein Stability, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.